
Sign up to save your podcasts
Or
Drug development is a highly expensive, risky venture for investors and researchers alike. Dr. Sasha Krupnick, chief of thoracic surgery and director of the lung transplant program for the University of Maryland Medical System, joins Justin to discuss why biotech needs more outsider perspectives, government support, and risk-takers to get the next industry-shaking innovation off the ground. Dr. Krupnick explains what led him from surgery to oncological drug discovery, why Big Pharma isn’t healthcare’s big bad, and why you should always bet on the surgeon.
Justin and Dr. Krupnick have a lively conversation around some tricky questions: What’s wrong with the drug development process today? What’s the role of small biotech and venture capital organizations in an industry dominated by massive developers? And why are so many potential cures for life-limiting illnesses dying on the vine?
To learn more about Definitive Healthcare, please visit us at definitivehc.com.
5
1111 ratings
Drug development is a highly expensive, risky venture for investors and researchers alike. Dr. Sasha Krupnick, chief of thoracic surgery and director of the lung transplant program for the University of Maryland Medical System, joins Justin to discuss why biotech needs more outsider perspectives, government support, and risk-takers to get the next industry-shaking innovation off the ground. Dr. Krupnick explains what led him from surgery to oncological drug discovery, why Big Pharma isn’t healthcare’s big bad, and why you should always bet on the surgeon.
Justin and Dr. Krupnick have a lively conversation around some tricky questions: What’s wrong with the drug development process today? What’s the role of small biotech and venture capital organizations in an industry dominated by massive developers? And why are so many potential cures for life-limiting illnesses dying on the vine?
To learn more about Definitive Healthcare, please visit us at definitivehc.com.